Volume 11, Issue 1 (6-2025)
Caspian J Reprod Med 2025, 11(1): 12-16 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Tsompos C, Panoulis C, Triantafyllou A, Zografos C, Zografos G C, Papalois A. Histologic comparison of the fallopian pathologic effects of erythropoietin and U-74389G. Caspian J Reprod Med 2025; 11 (1) :12-16
URL: http://caspjrm.ir/article-1-262-en.html
URL: http://caspjrm.ir/article-1-262-en.html
Constantinos Tsompos * 
, Constantinos Panoulis , Aggeliki Triantafyllou , Constantinos Zografos , George C. Zografos , Apostolos Papalois
, Constantinos Panoulis , Aggeliki Triantafyllou , Constantinos Zografos , George C. Zografos , Apostolos Papalois
Department of Gynecology, General Hospital of Athens “G. Gennimatas”, Attiki, HELLAS , constantinos1tsompos@gmail.com
Abstract: (1149 Views)
Background: This study compared the effects of erythropoietin (Epo) and the antioxidant lazaroid U-74389G (L) on fallopian pathology in a rat model of fallopian ischemia-reperfusion (FIR). The comparison was based on two preliminary studies evaluating the effects of each drug in an FIR animal model.
Methods: Fallopian pathology was assessed at two endpoints: 60 minutes (groups A, C, E) and 120 minutes (groups B, D, F) of reperfusion. Groups A and B received no drugs, groups C and D received Epo, and groups E and F received U-74389G.
Results: The Epo study showed a non-significant reduction in total fallopian pathology within the “lesion-free” grade by -0.01 (95% CI: -0.09 to 0.06). The U-74389G study showed a non-significant increase in pathology by 0.01 (95% CI: -0.05 to 0.06). Co-evaluation indicated that Epo slightly ameliorated fallopian pathology, while U-74389G slightly worsened it, though the difference was non-significant.
Conclusion: Epo demonstrates a slight, non-significant superiority over U-74389G in restoring fallopian pathology, potentially applicable in clinical settings.
Keywords: Erythropoietin, Fallopian tubes, Ischemia, Reperfusion, U-74389G
Methods: Fallopian pathology was assessed at two endpoints: 60 minutes (groups A, C, E) and 120 minutes (groups B, D, F) of reperfusion. Groups A and B received no drugs, groups C and D received Epo, and groups E and F received U-74389G.
Results: The Epo study showed a non-significant reduction in total fallopian pathology within the “lesion-free” grade by -0.01 (95% CI: -0.09 to 0.06). The U-74389G study showed a non-significant increase in pathology by 0.01 (95% CI: -0.05 to 0.06). Co-evaluation indicated that Epo slightly ameliorated fallopian pathology, while U-74389G slightly worsened it, though the difference was non-significant.
Conclusion: Epo demonstrates a slight, non-significant superiority over U-74389G in restoring fallopian pathology, potentially applicable in clinical settings.
Keywords: Erythropoietin, Fallopian tubes, Ischemia, Reperfusion, U-74389G
Type of Study: Original Research |
Subject:
Obstetrics and Gynecology
Received: 2025/03/5 | Accepted: 2025/06/28 | Published: 2025/06/29
Received: 2025/03/5 | Accepted: 2025/06/28 | Published: 2025/06/29
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
